ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) top owners are individual investors with 34% stake, while 29% is held by institutions [Yahoo! Finance]
ProQR to Participate in 8th Annual Evercore Healthcare Conference [Yahoo! Finance]
ProQR to Participate in 8th Annual Evercore Healthcare Conference
ProQR Therapeutics (NASDAQ:PRQR) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.